Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Prozac Documents Deemed "Missing" Were Already Available, Lilly Says

This article was originally published in The Pink Sheet Daily

Executive Summary

The documents which appeared in the British Medical Journal were shared with FDA, published in medical journals or produced through legal discovery over 10 years ago, Lilly says. The company maintains the medical journal "published data without validating the information."

You may also be interested in...



Lilly Launches PR Blitz On Prozac To Dispute Journal's Safety Claims

Full-page ad in major newspapers defends Lilly's handling of "missing" Prozac safety data and urges patients not to discontinue use of antidepressant based solely on media reports. Company also questions British Medical Journal's use of adverse event reports to draw conclusions about fluoxetine's safety profile.

Lilly Launches PR Blitz On Prozac To Dispute Journal's Safety Claims

Full-page ad in major newspapers defends Lilly's handling of "missing" Prozac safety data and urges patients not to discontinue use of antidepressant based solely on media reports. Company also questions British Medical Journal's use of adverse event reports to draw conclusions about fluoxetine's safety profile.

Michael Moore Gives Sicko New Life

Filmmaker has heightened his focus on a documentary looking at the American health care system, including the drug industry. Handicapping of Fahrenheit 9/11's chances in the Oscar race appears to be one factor behind renewing work on the project.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS061035

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel